[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
IJRR Information::
For Authors::
For Reviewers::
News & Events::
Web Mail::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Hard Copy 2322-3243
Online 2345-4229
Online Submission
Now you can send your articles to IJRR office using the article submission system.



:: Volume 21, Issue 4 (10-2023) ::
Int J Radiat Res 2023, 21(4): 727-732 Back to browse issues page
The role of stereotactic body radiotherapy (SBRT) in the treatment of recurrent / progressive lung lesions after primary treatment
H. Demir , S. Özdemir , N. Işık , G. Yaprak
Department of Radiation Oncology, University of Health Sciences Turkey, Kartal Lutfi Kirdar City Hospital, Istanbul, Turkey , alidmr198-idmr198@gmail.com
Abstract:   (620 Views)
Background: To evaluate treatment outcomes and toxicity of pulmonary SBRT for intrathoracic recurrence in patients with locally advanced NSCLC treated as a combination of surgery, radiotherapy or chemotherapy. Materials and Methods: A total of 46 patients with NSCLC who received thoracic SBRT for local or non local intrapulmonary recurrent lesions in our department from 2009 to 2019 were retrospectively enrolled in this study. The patients received median 43.4 Gy (25 Gy -60 Gy) radiotherapy using the CyberKnife radiosurgery system in median 3.6 fractions (range, 1-8).Univariate and multivariate Cox regression analyses were performed on the factors predicting outcomes. Results: The median follow up time after SBRT was 23.5 months. Treatment of the primary tumor consisted of surgical resection, radiochemotherapy, and systemic therapy in 25, 8 and 13 patients, respectively. İsolated local recurrence, intrathoracic recurrence and distant metastasis were detected in 5 (10.9%), 12 (26.1%) and 8 (17.4%) patients, respectively. Kaplan-Meier analysis of 2 year OS, PFS and LC for all tumors treated after SBRT were; 51%, 56% and 91%, respectively. In parameters related to patient and treatment; no statistical significance was found affecting local control and survival.(p>0.05). Grade 2 radiation pneumonitis and chest wall pain were observed in 2 (4.3%) and 1 (2.1 %) patients. Grade 3 toxicity was detected in 3 ( 6.5%) cases. Conclusion: Pulmonary SBRT for recurrent NSCLC is a good treatment option with favourable LC and promising survival. SBRT can be an effective treatment modality in the treatment of patients with local/limited pulmonary relapses with acceptable toxicity rates.
Keywords: Non-small cell lung cancer, recurrence, stereotactic body radiotherapy.
Full-Text [PDF 778 kb]   (445 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
1. 1. Park J, Park JW, Kang MK (2019) Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma. Yeungnam University Journal of Medicine, 36(3): 192-200. [DOI:10.12701/yujm.2019.00269] [PMID] []
2. Rosenzweıg K (2017) Stereotactic body radiation therapy as an alternative to surgery in early-stage non-small-cell lung cancer. Oncology, 31(6): 492-8.
3. Milano MT (2019) Stereotactic body radiotherapy as salvage treatment for recurrence of non-small cell lung cancer after prior surgery or radiotherapy. Translational Lung Cancer Research, 8(1): 78. [DOI:10.21037/tlcr.2018.08.15] [PMID] []
4. Zheng X, Schipper M, Kidwell K, et al. (2014) Survival outcome after SBRT and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J RadiatOncol Biol Phys, 90(3): 603-611. [DOI:10.1016/j.ijrobp.2014.05.055] [PMID]
5. Simone II CB, Wildt B, Haas AR, et al. (2013) Stereotactic body radiation therapy for lung cancer. Chest, 143(6): 1784-1790. [DOI:10.1378/chest.12-2580] [PMID]
6. He C, Liu YM, Cerra-Franco A, et al. Long-term survival after salvage SBRT for recurrent or secondary non-small cell lung cancer after prior surgery or radiation therapy. J Clin Oncol 2018; 36: abstr 8558. [DOI:10.1200/JCO.2018.36.15_suppl.8558]
7. Milano MT, Mihai A, Kong FM (2018) Review of thoracic reirradiation with stereotactic body radiation therapy: A focus on toxicity risks. Pract Radiat Oncol, 8:251-65. [DOI:10.1016/j.prro.2018.01.008] [PMID]
8. Videtic GM, Donington J, Giuliani M, et al. (2017) SBRT for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Practical Radiation Oncology, 7(5): 295-301. [DOI:10.1016/j.prro.2017.04.014] [PMID]
9. James K, Eisenhauer E, Christian M, et al. (1999) Measuring response in solid tumors: unidimensional versus bidimensional measurement. Journal of the National Cancer Institute, 91(6): 523-528. [DOI:10.1093/jnci/91.6.523] [PMID]
10. Trotti A, Colevas AD, Setser A, et al. (2003) CTCAE v3.0: development of a comprehensive grading for the adverse effects of cancer treatment. Seminars in Radiation Oncology, 13(3): 176-181. [DOI:10.1016/S1053-4296(03)00031-6] [PMID]
11. Dingemans AMC, Hendriks LE, Berghmans T, et al. (2019) Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report. Journal of Thoracic Oncology, 14(12): 2109-2119. [DOI:10.1016/j.jtho.2019.07.025] [PMID]
12. Lo SS, Fakiris AJ, Chang EL, et al. (2010) Stereotactic body radiation therapy: a novel treatment modality. Nature Reviews Clinical Oncology, 7(1): 44-54. [DOI:10.1038/nrclinonc.2009.188] [PMID]
13. Kelly P, Balter PA, Rebueno N, et al. (2010) SBRT for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys, 78(5): 1387-1393. [DOI:10.1016/j.ijrobp.2009.09.070] [PMID] []
14. Ceylan C, Hamaci A, Ayata H, et al. (2017) Re-irradiation of locoregional NSCLC recurrence using robotic SBRT. Oncology Research and Treatment, 40(4): 207-214. [DOI:10.1159/000457129] [PMID]
15. Timmerman RD, Paulus R, Pass, HI, et al. (2018) Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial. JAMA Oncology, 4(9): 1263-1266. [DOI:10.1001/jamaoncol.2018.1251] [PMID] []
16. Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. (2012) Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-smallcell lung cancer: a retrospective analysis. Lancet Oncol, 13: 802-809. [DOI:10.1016/S1470-2045(12)70242-5] [PMID]
17. Matsuo Y, Shibuya K, Nagata Y, et al. (2012) Preliminary report of late recurrences, at 5 years or more, after SBRT for non-small cell lung cancer. J Thoracic Oncology, 7(2): 453-456. [DOI:10.1097/JTO.0b013e31823c5b29] [PMID]
18. Parks J, Kloecker G, Woo S, Dunlap NE (2016) SBRT as salvage for intrathoracic recurrence in patients with previously irradiated locally advanced non-small cell lung cancer. American Journal of Clinical Oncology, 39(2): 147-153. [DOI:10.1097/COC.0000000000000039] [PMID]
19. Kilburn JM, Kuremsky JG, Blackstock, et al. (2014) Thoracic re-irradiation using SBRT techniques as first or second course of treatment. Radiotherapy and Oncology, 110(3): 505-510. [DOI:10.1016/j.radonc.2013.11.017] [PMID] []
20. Patel NR, Lanciano R, Sura K, et al. (2015) SBRT for re-irradiation of lung cancer recurrence with lower biological effective doses. J Radiat Oncol, 4(1): 65-70. [DOI:10.1007/s13566-014-0175-2] [PMID] []
21. Horne ZD, Dohopolski MJ, Clump DA, et al. (2018) Thoracic reirradi. with SBRT for residual/recurrent and new pri. NSCLC within or adjacent to a prior high-dose radiation field. Practical Radiat Oncol, 8(3): e117-e123. [DOI:10.1016/j.prro.2017.11.011] [PMID]
22. Agolli L, Valeriani M, Carnevale A, et al. (2015) Role of salvage SBRT in post-surgical loco-regional recurrence in a selected population of NSCLC patients. Anticancer Research, 35(3): 1783-1789.
23. Keidar Z, Haim N, Guralnik L, et al. (2004) PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. Journal of Nuclear Medicine, 45(10): 1640-1646.
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Demir H, Özdemir S, Işık N, Yaprak G. The role of stereotactic body radiotherapy (SBRT) in the treatment of recurrent / progressive lung lesions after primary treatment. Int J Radiat Res 2023; 21 (4) :727-732
URL: http://ijrr.com/article-1-5067-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 4 (10-2023) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4652